You are here
Thrombotargets opens new round to finish phase III of drug for haemorrhages
Biotechnology company Thrombotargets has opened a round of funding looking to raise €5.5 million to complete development of its topical treatment for haemorrhages during surgery. The drug, known as TT-173, has begun phase III clinical trials. The Castelldefels-based company has been working on this product for 15 years now.
The main shareholder in Thrombotargets is Biotech Angels and the chairman of the board of directors is perfume businessman Ramón Béjar. The board of directors is formed by Ignasi Miquel, Pilar Sánchez i Jesús Murat. The company was started in 2005, developing the BioplatformScreen platform used to screen molecules.
Photo: Ramón Béjar, CEO of Thrombotargets Europe. ©Thrombotargets